参考文献/References:
[1] Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short term outcomes of ST-segment elevation myocardial infarction and non-ST segment elevation myocardial infarction in patients with chronic kidney disease:a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry [J]. Circulation,2010,121(3):357-365.
[2] Baber U,Chandrasekhar J,Sartori S,et al. Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A Report From the PROMETHEUS Study[J]. J ACC Cardiovasc Interv,2017,10(20):2017-2025.
[3] Edfors R,Sahlén A,Szummer K,et al. Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function [J].Heart,2018,104(19):1575-1582.
[4] Bonello L,Anqiolillo DJ,Aradi D,et al. P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes[J].Circulation,2018,138(15):1582-1596.
[5] Melloni C,Cornel JH,Hafley G,et al.Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes:insights from the TRILOGY ACS Trial[J]. Eur Heart J Acute Cardiovasc Care,2016,5(6):443-454.
[6] Tantry US,Bonello L,Aradi D,et al.Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding[J]. J Am Coll Cardiol,2013,62(24):2261-2273.
[7] Stone GW,Witzenbichler B,Weisz G,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents(ADAPT-DES):a prospective multicentre registry study[J].Lancet,2013,382(9892):614-623.
[8]Windecker S,Kolh P,Alfonso F,et al,2014 ESC /EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2014,35(37):2541-2619．
[9] O’ Gara PT,Kushner FG,Ascheim DD,et al. 2013 ACCF /AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].J Am Coll Cardiol,2013,61(4):e78-e140．
[10] Husted S,van Giezen JJ. Ticagrelor:the first reversibly binding oral P2Y12 receptor antagonist [J]. Cardiovasc Ther,2009,27(4):259-274.
[11] Popma JJ,Berger P,Ohman EM,et al. Antithrombotie therapy during percutaneous coronary intervention:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3):57.
[12] Parikh PB,Jeremias A,Naidu SS,et al. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention[J]. Catheter Cardiovasc Interv,2012,80(3):352-357.
[13] Chou MT,Wang JJ,Sun YM,et al. Epidemiology and mortality among dialysis patients with acute coronary syndrome:Taiwan National Cohort Study[J].Int J Cardiol,2013,167(6):2719-2723.
[14] Butler K,Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment[J]. J Clin Pharmacol,2012,52(9):1388-1398.
[15] 王喜梅,吴永健,杨跃进,等. 慢性肾功能不全与急性冠状动脉综合征的研究进展[J].心血管病学进展,2012,33(1):21-23.
[16] Baber U,Stone GW,Weisz G,et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes[J]. JACC Cardiovasc Imaging,2012,5(3 suppl):S53-S61.
[17] Takagi M,Wada H,Mukai K,et al. Increased activated protein C:protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis[J]. Clin Appl Thromb Hemost,1999,5(2):113-116.
[18] Bonomini M,Dottori S,Amoroso L,et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia[J]. J Thromb Haemost,2004,2(8):1275-1281.
[19]Thijs A,Nanayakkara PW,Ter Wee PM,et al. Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study[J]. Clin Nephrol,2008,70(4):325-331.
[20] Molino D,de Lucia D,Gaspare De Santo N. Coagulation disorders in uremia[J]. Semin Nephrol,2006,26(1):46-51.
[21] Landray MJ,Wheeler DC,Lip GY,et al. Inflammation,endothelial dysfunction, and platelet activation in patients with chronic kidney disease:the Chronic Renal Impairment in Birmingham(CRIB) study[J]. Am J Kidney Dis,2004,43(2):244-253.
[22] Wratten ML,Tetta C,de Smet R,et al. Uremic ultrafiltrate inhibits platelet-activating factor synthesis[J]. Blood Purif,1999,17(2-3):134-141.
[23] Thekkedath UR,Chirananthavat T,Leypoldt JK,et al. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa[J]. Am J Hematol,2006,81(12):915-926.
[24] Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC) and of the European Association for Cardio-Thoracic Surgery(EACTS) [J]. Eur Heart J,2018,39(3):213-260.
[25] Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2014,130(25):344-426.
[26]中国医师协会心血管内科医师分会血栓防治专业委员会,中华医学会心血管病分会介入学组,中华心血管病杂志编辑委员会.替格瑞洛临床应用中国专家共识[J]. 临床军医杂志,2016,44(5):444-453.
[27] James S,Budaj A,Aylward P,et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial[J].Circulation,2010,122(11):1056-1067.
[28] Bonello L,Laine M,Lemesle G,et al. Meta-analysis of potent P2Y12-ADP receptor antagonist therapy compared to clopidogrel therapy in acute coronary syndrome patients with chronic kidney disease[J].Thromb Haemost,2018,118(10):1839-1846.
[29] Edfors R,Sahlen AS,Szummer KS. Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction in relation to renal function:1-year SWEDEHEART registry data[J]. Heart,2018,104(19):1575-1582.
[30] Wang H,Qi J,Li Y,et al. Pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic kidney disease[J]. Br J Clin Pharmacol,2018,84(1):88-96.
[31]Jeong KH,Cho JH,Woo JS,et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study[J]. Am J Kidney Dis,2015,65(6):916-924.
[32] Desai RJ,Spoendlin J,Mogun H,et al. Contemporary time-trends in use of antiplatelet agents among patients with acute coronary syndrome and comorbid diabetes mellitus or chronic kidney disease[J]. Pharmacotherapy,2017,37(10):1322-1327.
[33]Alexopoulos D,Xanthopoulou I,Plakomyti TE,et al.Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis[J].Am J Kidney Dis,2012,60(2):332-333.
[34] 张雁,刘强,左辉华,等.替格瑞洛用于行 PCI 术的慢性肾功能不全急性冠脉综合征患者的临床研究[J].中国医药导刊,2017,19(11):1135-1138.
[35] Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study[J]. Lancet,2010,375(9711):283-293.
相似文献/References:
[1]陈艳,综述,袁晋青,等.替格瑞洛临床应用新进展[J].心血管病学进展,2016,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
CHEN Yan,YUAN Jinqing.The Updates of Ticagrelor Use in Clinical Practice[J].Advances in Cardiovascular Diseases,2016,(5):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
[2]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[3]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(5):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(5):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(5):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[8]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(5):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[9]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]
[10]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[11]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(5):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[12]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(5):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[13]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(5):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[14]王晓妍 崔炜.替格瑞洛治疗急性冠脉综合征时引起缓慢性心律失常的研究进展[J].心血管病学进展,2021,(7):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]
WANG Xiaoyan,CUI Wei.Bradyarrhythmia Caused by Ticagrelor in Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]